CorEvitas and Inovalon leverage advanced analytics to provide a holistic view of the patient


WALTHAM, Massachusetts, September 21, 2021 / PRNewswire / – CorEvitas, LLC, the benchmark leader in real longitudinal data on autoimmune and inflammatory disease, today announced that it has broadened its engagement with Inovalon (NASDAQ: INOV) A life sciences business unit specializing in data-driven healthcare analysis and strategic advisory services, to provide a holistic view of patients with rheumatoid arthritis or psoriasis.

In conjunction with granular clinical data from CorEvitas on validated physician evaluations and reported patient outcomes, this collaboration focuses on rheumatoid arthritis and psoriasis and highlights one of many critical use cases focused on chronic diseases of MORE by Inovalon.² Registration® dataset, which today provides the healthcare market with insight into tens of millions of patients with key chronic conditions that contribute to poor clinical outcomes and rising healthcare costs in United States.

“The healthcare market, especially life science companies and healthcare plans, wanted to establish more definitive links between clinical measurements, patient adherence, laboratory values, resource use health and economic outcomes throughout the patient journey, ”said John E. Linnehan, Practice Director of Inovalon’s Health Economics and Advanced Analysis Team. “We are delighted to be working with CorEvitas to accelerate this knowledge by initially focusing on rheumatoid arthritis and psoriasis. “

With a comprehensive overview of individual rheumatoid arthritis or psoriasis patients, unique from a given data set, CorEvitas experts have the ability to assess real-world and longitudinal dynamics between demographics, clinical features, functional status, outcome measures, laboratory values, health resource use and reported economic outcomes. The insights enabled by these analyzes can advance clinical development, inform trial design and recruitment, inform value stories, and inform patient-specific intervention plans.

Raymond Hill, President and CEO of CorEvitas, said: “As an organization, we recognize the immeasurable value of understanding the whole patient. By deepening our collaboration with Inovalon, we can leverage data-driven insights that provide integrated and actionable insights for this symbiotic expansion of real-world evidence to ultimately advance healthcare to its next level. “

CorEvitas collects comprehensive, forward-looking and structured benchmark data that provides unmatched clinical depth and granularity. Data collected from more than 475 sites in the United States, Canada, and Japan make CorEvitas the largest network of real-world investigators providing prospective data for patients with autoimmune and inflammatory diseases.

“We’re excited to be able to provide our subscriber base with these extended use cases,” said Leslie Harrold, MD, MPH, Scientific Director of CorEvitas. “So much real-world data is siled. By connecting data, we can better understand our patients and their needs, thereby improving paradigms of care. “

About CorEvitasSM

CorEvitas is the leading provider of real world evidence. Through syndicated registry data and analytics services, CorEvitas helps biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers and regulators. CorEvitas operates eight major autoimmune and inflammatory registries in the United States, Canada, and Japan, collecting data from nearly 500 participating investigator sites. In addition to supporting hundreds of manuscripts and abstracts, CorEvitas supported post-approval safety commitments for several newly approved treatments in autoimmune diseases for US and European regulators. CorEvitas is headquartered in Waltham, MA. Its subsidiary, HealthiVibe, complements and reinforces the company’s strong presence in disease registries by providing cutting-edge expertise in supporting innovative, evidence-based patient engagement initiatives throughout the product lifecycle. The Health Unlocked The technology platform houses more than 1.4 million patients in hundreds of condition-specific communities and dramatically expands the reach of patient experiential data. Through Qi Health, CorEvitas has access to a wide range of UK and international primary and secondary care datasets, as well as close relationships with the NHS and major UK academic institutions. Vestrum Health, a leader in data analysis of retinal practice, electronic health records, provides insightful views of retinal disease throughout the drug lifecycle. CorEvitas is an Audax Private Equity holding company.

About Inovalon
Inovalon is a leading provider of cloud-based platforms enabling data-driven healthcare. Thanks to Inovalon ONE® Platform, Inovalon brings to the market a nationwide capacity to interconnect with the healthcare ecosystem, aggregate and analyze data in real time and enable the application of the resulting information to generate a significant impact on the place of care. Leveraging its platform, unprecedented proprietary data sets, and industry-leading subject matter expertise, Inovalon helps improve care, efficiency and financial performance across the entire healthcare ecosystem. health. From healthcare plans and supplier organizations to pharmaceutical, medical device and diagnostic companies, Inovalon’s unique value is delivered through the effective progression of “Turning data into knowledge and knowledge into action.”®. “Supporting thousands of customers, including the 25 of the 25 best US healthcare plans, the 25 of the 25 largest global pharmaceutical companies, 24 of the top 25 US healthcare provider systems and many of the top US healthcare providers pharmaceutical organizations, device manufacturers and other components of the healthcare industry, Inovalon technology platforms and analyzes are informed by data relating to more than one million physicians, 584,000 clinical establishments, 338 million Americans and 63 billion medical events.

CorEvitas, LLC
Erem Latif
(508) 408-5529
[email protected]



Comments are closed.